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Toxicityhighly charged protein that is normally predominantly localized around synaptic
vesicles in presynaptic terminals. Although the function of this protein is still ill-deﬁned, genetic studies have
demonstrated that point mutations or genetic alteration (duplications or triplications) that increase the
number of copies of the α-synuclein (SCNA) gene can cause Parkinson's disease or the related disorder
dementia with Lewy bodies. α-Synuclein can aberrantly polymerize into ﬁbrils with typical amyloid
properties, and these ﬁbrils are the major component of many types of pathological inclusions, including
Lewy bodies, which are associated with neurodegenerative diseases, such as Parkinson's disease. Although
there is substantial evidence supporting the toxic nature of α-synuclein inclusions, other modes of toxicity
such as oligomers have been proposed. In this review, some of the evidence for the different mechanisms of
α-synuclein toxicity is presented and discussed.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Parkinson's disease (PD) is a progressive, neurodegenerative
disorder characterized by bradykinesia, resting tremor, cogwheel
rigidity and postural instability [1,2] associated with the loss of
dopaminergic (DA) neurons in the substantia nigra (SN) pars
compacta [3,4]. Although the major pathological hallmarks of PD,
Lewy bodies (LB) and Lewy neurites (LN), were originally observed in
1912 [5], α-synuclein (α-syn) was not identiﬁed as the major
component of these proteinaceous inclusions until 1997 [6] following
the discovery of PD kindred with point mutations in the α-syn gene
(SNCA) [7]. In addition to PD, the presence of α-syn pathological
inclusions is one of the deﬁning features of several other neurode-
generative diseases, including dementia with Lewy bodies (DLB), LB
variant of Alzheimer's disease and multiple system atrophy (MSA)
[6,8–13]. Furthermore α-syn inclusions are also found in a signiﬁcant
percentage of other neurodegenerative disorders, including neurode-
generation with brain iron accumulation type-1, Down's syndrome,
progressive autonomic failure and familial and sporadic Alzheimer's
disease [14–21]. Collectively these diseases have been deﬁned as α-
synucleinopathies. This review will focus on the potential molecular
mechanisms by which α-syn may cause neurodegeneration.
2. The α-syn protein
α-Syn is a small, highly charged 140-amino acid residue protein
characterized by several major regions: 1) an amino-terminal region1 215 573 2236.
Giasson).
ll rights reserved.containing several imperfect KTKEGV repeats, 2) a hydrophobic
center domain also referred to as the non-amyloid component
(NAC) region, and 3) a highly negatively charged carboxy-terminus
region (Fig. 1). α-Syn is a soluble, heat-stable and natively
“unfolded” protein [22,23]. It is predominantly expressed in central
nervous system (CNS) neurons, where it is localized at presynaptic
terminals in close proximity to synaptic vesicles [24–27] and can
associate with lipid membranes by forming amphiphatic α-helices,
as shown in vitro [22,28–31]. Although the function of α-syn is still
poorly understood, several studies suggest that it is involved in
modulating synaptic transmission, the density of synaptic vesicles
and neuronal plasticity [26,27,32–34], as well as provide a
supportive role in the folding/refolding of SNARE proteins critical
for neurotransmitter release, vesicle recycling and synaptic integrity
[35]. However, knockout mouse models of α-syn are not lethal, and
brain morphology is intact, suggesting that α-syn is not required for
neuronal development and/or that compensatory pathways are
present [33,34]. In vitro studies have shown that the carboxy-
terminal region of α-syn is required for chaperone-like activity [36–
38]. α-Syn can also associated with many proteins [39] and can
regulate the activity of several enzymes, including tyrosine hydro-
xylase, the rate-limiting enzyme in dopamine production [40,41],
mitogen-activated protein kinases (MAPKs) [42], and phospholipase
D (PLD) [43,44].
3. Disease-causing α-syn mutations
The most direct and compelling evidence for a fundamental role of
α-syn in the pathogenesis of α-synucleinopathies is the causal
relationship between genetic mutations and disease. The mutation
Fig. 1. Amino acid sequence and regions of α-syn. α-Syn is composed of: 1) an amino-
terminal domain (black) containing several imperfect KTKEGVmotifs (blue underline);
2) a hydrophobic center (purple) termed non-amyloid component (NAC); and 3) a
negatively charged carboxy-terminus (green). Three familial mutations in α-syn (red)
have been identiﬁed in patients with PD.
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of the SNCA (α-syn) gene was ﬁrst identiﬁed in a large Italian family
(Contursi) and three small Greek families with autosomal dominant
PD [7]. Thereafter, the Ala53Thr mutation was identiﬁed in at least 8
additional PD kindreds [45–48], and another autosomal dominant
mutation (Ala30Pro) was identiﬁed in a German kindred [49]. The
Glu46Lys mutation in α-syn was identiﬁed in kindred manifesting
classical PD or PD with features of dementia associated with
widespread Lewy pathology, referred to as DLB [50]. In addition,
short chromosomal duplications or trisomies containing the SCNA
gene, plus relatively short ﬂanking regions on chromosome 4, were
discovered in patients with PD or DLB [51–53], indicating that a 50%
increase in the expression of α-syn is sufﬁcient to cause disease.
4. Formation of α-syn amyloidogenic inclusions
α-Syn ﬁlaments (10–15 nm-wide) are the major ultrastructural
component of pathological inclusions characteristic of synucleino-
pathies [6,12,13]. These inclusions can occur in cell bodies such as
LBs that are present in neurons of patients with PD and DLB or such
as glial cytoplasmic inclusions (GCIs) that form in oligodendrocytes
of individuals with MSA. α-Syn inclusions can also present in the
processes of affected cells, forming for example dystrophic neurites
or large axonal swellings termed neuroaxonal spheroids [12,13].Fig. 2. Formation of α-syn polymeric intermediates and ﬁbrils. α-Syn in native, monomeri
changes, resulting in β-pleated sheet formation. This form of α-syn can take two pathways, o
ﬁbrils. The off-ﬁbril pathway can result in the formation of annular or other forms of ol
intermediate stages, which include protoﬁbrils, before maturing into long strands and becoIn vitro studies have shown that recombinant soluble α-syn can
readily polymerize into amyloidogenic ﬁbrils that are structurally
similar to those in human brains [54–57]. Polymerization of α-syn is a
nucleation dependent process, i.e. ﬁbril formation displays a lag phase
followed by a rapid increase in ﬁbril formation [57–60], and this lag
phase is dramatically reduced by the addition of a “seed” or “nucleus”
of pre-aggregated α-syn [59]. The polymerization of α-syn is
associated with a dramatic conformational change from random
coiled to predominantly β-pleated sheet [61–64], and it has been
proposed thatα-syn progresses from an unorderedmonomer through
partially folded intermediates, and ﬁnally elongates into “mature”
ﬁlaments [58].
The central hydrophobic region in α-syn is necessary for ﬁbrilliza-
tion [64,65] and this region is buried within the ﬁbril core, as
demonstrated by immuno-electron microscopy analysis and protei-
nase K resistance assays [64,66,67]. The negatively charged carboxy-
terminus negatively regulates ﬁbril formation such that deletions of
this region promotes ﬁbril formation [62,67]. The presence of the
amino-terminal region also reduces ﬁbrillogenesis, as deletions of
some of the repeats can accelerate ﬁlament formation [68].
The Ala53Thr and Glu46Lysα-syn proteins show increased rates of
self-assembly and ﬁbril formation [54,55,57,60,69–72]. This is con-
sistent with studies showing that the Ala53Thr α-syn preferentially
adopts a β-sheet conformation [73]. These in vitro data suggest that
the Ala53Thr and Glu46Lys α-syn mutations could be pathogenic
because of their increased propensity to form pathological inclusions.
In fact, α-syn, which contains both the Gly46Lys and Ala53Thr
mutations, ﬁbrillizes more rapidly than the Ala53Thr mutation alone,
and this protein is even more likely to conform to the amino-terminal
structure of α-syn in pathological inclusions, as detected by
conformational-speciﬁc antibodies [74].
While some reports suggest that Ala30Proα-syn forms ﬁbrils more
slowly than WT α-syn [69], this ﬁnding is not consistently observed
by others [55,57]. In addition, the Ala30Pro mutation appears to affect
α-syn properties independent of protein aggregation. The Ala30Pro
mutation may partially impaired the ability of α-syn to bind to brain
vesicles [35,75], likely due to a decreased likelihood to form α-helicesc form is mostly unstructured. Under certain conditions α-syn can undergo structural
ne which is off of the ﬁbrillar pathway, and the other which will eventually formmature
igomers that will never develop into mature ﬁbrils. The ﬁbrillar pathway undergoes
ming LBs or LNs.
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to presynaptic terminals [76]. This mutation can also directly impair
the in vitro chaperone-like activity of α-syn [36], and studies in mice
indicate that Ala30Pro α-syn is deﬁcient in the ability of refolding
SNARE proteins [35], which may be due to its reduced ability to
interact with vesicles.
5. Protoﬁbril/oligomer toxicity hypothesis
The polymerization of α-syn from unstructured monomer to
mature amyloid ﬁbrils rich in β-sheets proceeds through the
formation of several altered-sized oligomers and polymers that can
be visualized and assayed by electron microscopy, atomic force
microscopy and size-exclusions chromatography (Fig. 2) [69,77].
Several of these intermediates (as well as products that may not
culminant into ﬁbrils) have been described as spheres (2–6 nm in
size), chains of spheres (also termed protoﬁbrils) and rings resem-
bling circular protoﬁbrils (also termed annular protoﬁbrils) [69,77,78].
Several ﬁndings have suggested that protoﬁbrils or some forms of
α-syn oligomers may be toxic. This hypothesis is analogous to the
proposal that amyloid assembly intermediates of other amyloidogenic
proteins such as the Aβ peptide involved in Alzheimer's disease may
be toxic [77,79]. The initial observation that Ala30Pro α-syn may have
a tendency to accumulate as oligomers instead of mature ﬁbrils led to
the suggestion that α-syn may have a similar toxic mechanism
[69,77]. In addition, the formation of such oligomers in vitro is shown
to increase leakiness of synthetic lipid vesicles [80]. Two mechanisms
have been proposed to explain this effect of α-syn oligomers on
membrane permeability: 1) α-syn annular oligomers may integrate
into membrane resulting in the formation of pores or channel-like
structures that could cause uncontrolledmembrane permeability [77–
79,81–83], and 2) oligomers enhance the ability of ions to move
through the membrane bilayer, without the formation of pores [84].
Direct in vivo data supporting the “toxic oligomeric α-syn
hypothesis” are still relatively limited and most of the evidence is
circumstantial. There are studies in cultured cells that support this
notion, but others demonstrated a lack of association between
intracellular oligomer and toxicity (see the section on “Cell culture
studies of α-syn toxicity” below). There is also a paucity of animal
studies to directly support this hypothesis, but this could be related to
the difﬁculties in monitoring these species in vivo due to their
transitory nature.
6. Cell culture studies of α-syn toxicity
Several studies in cultured cells indicate that the expression of
mutants of α-syn (Ala53Thr or Ala30Pro) can sensitize cells to toxic
challenges; however, the results of these studies are not unequivocal
[85–96]. In some studies, toxicity induced by the expression of mutant
α-syn is associated with the formation of α-syn aggregates
[88,89,91,97]. The over-expression of wild-type (WT) α-syn in some
settings has also been reported to render cells more vulnerable to
cellular challenges [42,94,97–103]. In striking contrast, other studies
have shown that expression of WT α-syn can protect against cellular
stresses [88,99,104–109]. Nevertheless, several different mechanisms,
including proteasomal inhibition, affects on signal transduction
pathways, mitochondrial alterations, increased levels of free radicals,
and membrane clustering of dopamine transporter resulting in
increased dopamine uptake, have been proposed as toxic mechanisms
associated with the expression of WT or mutant α-syn
[42,90,92,96,98–100,110].
Several studies have shown that the extracellular addition of in
vitro generated α-syn oligomers to cultured cells can lead to toxicity
[111,112]. Although these studies are artiﬁcial, there is some data to
suggest that α-syn that may normally be secreted by cells or released
due to cell death can be directly or indirectly toxic to other adjacentcells (see [113] and references therein). Some studies suggest that the
intracellular formation of α-syn oligomers in H4 neuroglioma cells is
associated with toxicity [114]. Conversely, others studies have shown
that the formation of abundant Ala53Thr α-syn oligomers in SH-SY5Y
cells induced by increasing intracellular catecholamine levels is not
associated with toxicity [115].
The reasons for the discrepancies in the results between the toxic
or protective effects of α-syn are not clear, but cell types, the
promoters and transfection methods used to overexpress α-syn, the
use of tagged protein versus native α-syn, the nature of the toxic
stimulus utilized, and the level of expression, may be important
factors [110].
7. Studies of α-syn toxicity in yeast (Saccharomyces cerevisiae)
Although no ortholog of α-syn exist in yeast, expression of
untagged WT α-syn or WT α-syn-EGFP in the yeast Saccharomyces
cerevisiae (S. cerevisiae) can inhibit cell growth and may result in cell
death [116–119]. When expressed at low levels or upon initial
expression at high levels, α-syn is localized to the plasma membrane,
but when expressed at high levels it subsequently forms cytoplasmic
inclusions that is associated with toxicity [116–118]. Expression of
Ala53Thr α-syn results in similar distribution proﬁles and toxicity. In
contrast, Ala30Pro α-syn displays both plasma membrane and diffuse
cytoplasmic localizations, does not form inclusions, and demonstrates
much reduced cell growth inhibition [116,117]. The altered distribu-
tion of Ala30Pro α-syn could be due to its reduced afﬁnity for lipid
membranes and/or targeting to the vacuole for degradation [119].
Further studies show that the α-syn inclusions in yeast are not
comprised of amyloid-like ﬁbrils, but instead are α-syn associated
with clusters of vesicles [116,120]. The expression of α-syn in S.
cerevisiae impairs endoplasmic reticulum (ER) to Golgi vesicle
trafﬁcking, which leads to the accumulation of these membranous
vesicles [116,118,120]. A genome-wide screen identiﬁed several
suppressors of these defects in ER-Golgi trafﬁcking, including the
Rab guanosine triphosphatase Ypt1p, which also suppresses α-syn
toxicity [118]. Although the importance of these ﬁndings as it relates
to the pathobiology of α-syn in humans is not completely clear, there
is some experimental evidence suggesting that the deleterious effects
of α-syn in this pathway may be relevant to disease. Expression of
Rab1 (the murine ortholog of YPT1) in Drosophila rescues toxicity
induced by expressing WT and Ala53Thr α-syn in DA neurons [118].
Similarly, expression of Rab1 can rescue the demise of DA neurons
induced by over-expressing Ala53Thr α-syn in cultured rat midbrain
primary neurons [118].
8. Studies of α-syn toxicity in Drosophila melanogaster
There are no known orthologs ofα-syn in Drosophila melanogaster;
nevertheless the ability to use this organism to identify genetic
modiﬁers and to conduct studies of neurodegeneration in a shorter
timeframe than inmammals has compelled the development ofα-syn
transgenic (tg) ﬂies. Expression of human α-syn in Drosophila is
reported to result in a selective age-dependent neuronal loss of DA
neurons, locomotor dysfunction and cytoplasmic inclusions, some of
which are composed to 7–10 nm wide ﬁlaments with additional
granular material similar to LBs [121]. Co-expression of the chaperone
heat-shock protein (Hsp) 70 can suppress neuronal degeneration,
while a dominant negative form of Hsp 70 increases DA neuronal loss
[122]. In addition, a drug that inhibits Hsp 90, a negative regulator of
heat shock response, also rescues DA neuronal loss. However, these
initial observations in α-syn tg ﬂies have been challenged since
locomotor dysfunction could not be replicated by others [123]. In
addition, the loss of DA neurons is not observed when a whole-mount
immunohistochemistry approach is used, compared to sequential
parafﬁn sectioning used in the other studies [123], suggesting that
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toxic effects that could alter neuronal morphology or the size of DA
neurons.
9. Studies of α-syn toxicity in Caenorhabditis elegans
There is also no known ortholog of α-syn in the worm Caenor-
habditis elegans (C. elegans), but the potential utility of this organism
to quickly identify genetic modiﬁers compelled studies to develop α-
syn tg models. However, the effects of expressing WT and mutants of
α-syn in DA neurons of C. elegans have been controversial. Lakso et al.
report that expression of WT or A53T human α-syn using pan-
neuronal or DA neuronal promoters cause a reduction in the number
of DA neuron cell bodies and processes [124]. Conversely, Kuwahara et
al. do not observe a demise of DA neurons using a DA-speciﬁc
promoter to express human WT, A30P or A53T α-syn, although a
decrease of neurites is noted [125]. It is suggested that the apparent
reduction in DA neurons observed by Lakso et al. could be due to a
reduction in the expression of the tg-expressed marker used to
monitor DA neurons, resulting from using the same promoter to
express α-syn [125]. Nevertheless, Kuwahara et al. report that the tg
expression of A53T or A30P α-syn results in a reduction in DA levels
associated with impairment in locomotor rate in response to food,
which in C. elegans is attributed to the function of DA neurons [125].
10. Mouse tg models of α-syn toxicity
Several tg mouse models expressing either WT or mutant
(Ala53Thr and Ala30Pro) α-syn have been reported. Masliah et al.
reported on the ﬁrst α-syn tg mouse lines that were generated [126].
In these mice neuronal expression ofWT humanα-syn is driven using
a platelet-derived growth factor-β (PDGF-β) promoter, which results
in the formation of amorphous, non-ﬁlamentous α-syn neuron
aggregates in the neocortex, the hippocampus, and occasionally in
the SN. A subset of α-syn inclusions is also ubiquitin positive, which is
characteristic of authentic human α-syn inclusions. However, in
contrast with typical α-syn inclusions in PD, a signiﬁcant portion of
the inclusions in these mice are located in the nucleus. The formation
α-syn aggregates in PDGF-β/α-syn tg mice is also associated with a
modest reduction in striatal tyrosine hydroxylase-positive terminals.
Interestingly, over-expression of β-syn, a proteinwith close homology
to α-syn, but unable to polymerize into amyloid ﬁbrils [64], by
transgenic cross breeding, reduces the numbers of α-syn inclusions,
ameliorates motor impairment and results in a partial rescue of
striatal tyrosine hydroxylase-positive terminals suggesting that β-syn
may prevent α-syn aggregation [127].
Since Alzheimer's disease pathology and PD often coincide in
patients, the effects of accumulating amyloid-β (Aβ) peptide, the
major component of senile plaques characteristic of Alzheimer's
disease, on α-syn pathobiology has been assessed using tg mice. The
PDGF-β/α-syn tgmice have been cross-bredwith a tgmousemodel of
Alzheimer's disease, where a disease-causing mutant form of the
human amyloid precursor protein (APP) is expressed resulting in the
production and accumulation Aβ extracellular inclusions [128]. The
expression of Aβ peptide in these bigenic mice is shown to potentiate
neuronal and presynaptic terminal loss, motor impairments and the
formation of ﬁbrillar intraneuronalα-synwhen compared to PDGF-β/
α-syn tg mice. These ﬁndings provide important information
supporting the notion that Aβ peptide, which is predominantly
extracellular, can promote the formation of intraneuronal α-syn
aggregates.
The PDGF-β/α-syn tg mice also have been used to generate
bigenic tg mice that overexpress rat Hsp 70, and Hsp 70 expression
is found to mitigate the formation of α-syn aggregates, suggesting
that Hsp 70 may have a role in refolding or degrading misfolded α-
syn [129].Other studies have used a Thy-1 promoter to drive the neuronal
expression of WT, Ala30Pro or Ala53Thr human α-syn in tg mice
[76,130–132]. In some of the Thy-1 tg mouse lines, expression of WT
or Ala53Thr α-syn results in the appearance of perikaryal and
neuritic accumulations of α-syn and age dependent motor impair-
ment associated with the degeneration of ventral root axons and
muscle denervation [130]. A subset of α-syn inclusions in these
mice are argyrophilic and immunoreactive for ubiquitin, but they
lack the ﬁlamentous characteristics of authentic human α-syn
inclusions. Kahle and colleagues generated Thy-1 tg mouse lines
expressing human WT or Ala30Pro α-syn. These Thy-1/WT-α-syn
and Thy-1/Ala30Pro-α-syn tg mice are reported to initially devel-
oped detergent-insoluble somatodendritic accumulations of human
α-syn that is not associated with any obvious phenotype
[76,131,133]. With aging the Thy-1/Ala30Pro-α-syn tg mice develop
neuronal cytoplasmic ﬁbrillar “amyloidogenic” inclusions that
resemble the properties of authentic α-syn inclusions as evidenced
by thioﬂavin S-reactivity, proteinase K resistance and ultrastructure
studies [132]. These inclusions are predominantly abundant in the
midbrain, brainstem, amygdala and spinal cord [132,133]. From
these studies reported by Kahle and colleagues, it is unclear if the
Thy-1/WT-α-syn tg mice develop age-dependent pathological
features similar to the Thy-1/Ala30Pro-α-syn transgenic mice or if
these changes are speciﬁc and exacerbated by the Ala30Pro
mutation [131,132]. The formation of amyloidogenic inclusions in
Thy-1/Ala30Pro-α-syn tg mice is associated with deterioration in
locomotor performance that progressed to spastic paralysis of the
hind limbs [128]. Furthermore, the speciﬁc formation of amyloido-
genic inclusions in the amygdale of Thy-1/Ala30Pro-α-syn is
correlated with a decline in cognitive performance [133].
Tg mice have also been generated that expressed either WT,
Ala53Thr or Ala30Pro human α-syn using the murine prion protein
promoter (PrP) [134,135]. PrP α-syn tg mice expressing Ala53Thr α-
syn, but not those expressing equivalent levels of WT or Ala30Pro α-
syn, develop amyloidogenic, 10–15 nm ﬁlamentous α-syn inclusions
in neurons (i.e. axonal spheroids, LB-like and LN-like lesions) that
replicate many of the biochemical and histological features of
authentic human synucleinopathies [134,135]. These α-syn inclusions
are predominantly observed in the spinal cord, brain stem, deep
cerebellar nuclei, and the thalamus. Similar to Thy-1/Ala30Pro α-syn
transgenic mice, the hippocampus and the SN are spared. Also similar
to Thy-1/Ala30Pro α-syn transgenic mice, PrP/Ala53Thr α-syn
transgenic mice display an age-dependent severe motor phenotype
that includes reduced ambulance, paralysis of the extremities usually
beginning at a hind limb that progress to quadriparesis and arched
back posture. These phenotypic features coincide with the accumula-
tion of ﬁlamentous intracytoplasmic α-syn neuronal inclusions. The
degeneration of motor axons is likely the main cause of the motor
phenotype in the PrP/Ala53Thr a-syn tg mice, as dramatic Wallerian
degeneration of ventral roots was observed [134]. Ultrastructure
studies show that α-syn ﬁlamentous axonal inclusions can trap
mitochondria and impair axonal transport leading to axonal swelling
containing vacuoles, vesicles and mitochondria [134]. The formation
of α-syn inclusions is also associated with motor neuron loss [136].
The increase propensity of Ala53Thr α-syn to polymerize into ﬁbrils
compared to WT or Ala30Pro α-syn [54,55,57] is the most likely
explanation for the formation of neurotoxic inclusions in PrP/
Ala53Thr α-syn tg mice, while PrP/WT α-syn tg or PrP/Ala30Pro α-
syn tg mice with similar expression do not display pathology. Since
the age-dependent phenotypic changes and pathologies in Thy/
Ala30Pro α-syn tg mice are similar to those in PrP/Ala53Thr α-syn tg
mice, but PrP/Ala30Pro α-syn tg mice are not affected, it is possible
that Thy/Ala30Pro α-syn tg mice have higher expression levels than
PrP/Ala30Pro α-syn tg mice. However, a direct comparison has not
been performed. This possibility is further supported by PrP/Ala30Pro
α-syn tg mice generated by Sudhöf and colleagues that display similar
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Ala53Thr α-syn tg mice [35,137].
Using their PrP/Ala30Pro α-syn tg mice, Sudhöf and colleagues
demonstrated that a dramatic increase in the level of the lipid-binding
protein Apolipoprotein E (ApoE) coincides with the motor impair-
ment and motor neuron loss associated with α-syn inclusions [137].
These ﬁndings are particularly interesting since speciﬁc ApoE
genotypic isoforms are important risk factors for Alzheimer's disease.
Further, ApoE can modulate the formation of α-syn pathology, since
bleeding these PrP/Ala30Pro α-syn tg mice on an ApoE null
background delays motor disease, while increasing survival, although
these processes are not completely abolished [137]. These ﬁndings
indicate that ApoE can be an important modulator of α-syn
aggregation and related pathogenesis, although the mechanisms are
not clearly deﬁned.
Since septin-4 (Sept4), a member of the septin family of
polymerizing GTP binding proteins that serve as scaffolds to anchor
or stabilize othermolecules, is present inα-synpathological inclusions
in human brains and interacts with α-syn [138], the effect of Sept4 on
α-syn pathobiology has been investigated in vivo in the PrP/Ala53Thr
α-syn tgmice described above. The breeding of PrP/Ala53Thrα-syn tg
mice on a Sept4 null background results in an exacerbation of
locomotor deterioration and neuronal loss associated with α-syn
inclusion formation [139]. These data suggest that Sept4 may act as a
suppressor of α-syn aggregation and resulting neurodegeneration.
Counterintuitively, the transgenic mice described above do not
develop substantial SN DA neuronal pathologies. For reasons that
remain enigmatic, it appears that, in contrast to humans, this
population of neurons in mice is resilient to the formation of α-syn
inclusions and degeneration. This notion is consistent with the lack of
pathology even when the a tyrosine hydroxylase promoter, which
drives express speciﬁcally in catecholaminergic neurons, is used to
generate WT, Ala53Thr or Ala30Pro α-syn tg mice [140].
Since α-syn inclusions in human brain contain C-terminally
truncated α-syn [112,141–143], which may be generated by incom-
plete 20 S proteasome degradation or calpain cleavage [112,144,145],
and C-terminal truncated α-syn ﬁbrillizes faster in vitro (see above),
Tofaris et al. created tg mice expressing C-terminal truncated α-syn
[146]. These tg mice express human α-syn missing the last 20 amino
acids (i.e. α-syn 1–120) driven by a rat tyrosine hydroxylase promoter
on an α-syn null background. In this model, α-syn 1–120 is expressed
in DA neurons of the SN and olfactory bulb, resulting in aggregates
with either granular and ﬁbrillar morphologies. Shrunken neuronal
perikarya and swollen axons of DA neurons are observed, but without
signiﬁcant neuronal loss. In another effort to study the effect of
truncated α-syn, transgenic mice were generated using rat tyrosine
hydroxylase promoter to express Ala53Thr human α-syn 1–130 (i.e.
lacking the last 10 amino acids) [147]. Animals that express this
truncated protein have a signiﬁcant loss of nigral DA neurons, which is
not observed in a similar tg line expressing full-length human α-syn.
However, the loss of DA neurons is shown to occur during
embryogenesis without the formation of α-syn inclusion. These
ﬁndings support that this form of truncated α-syn can be toxic in
nature, but its does not provide insights in the typical age-dependent
neurodegeneration associated with human diseases.
As GCIs in oligodendrocytes are key pathological features of MSA,
several tgmouse lines expressingWThumanα-syn in oligodendrocytes
were generated. Kahle et al. used aproteolipidprotein (PLP) promoter to
drive express α-syn speciﬁcally in oligodendrocytes, and these mice
develop detergent-insoluble aggregates with histological proﬁles that
resembled GCIs [148]. These mice demonstrate increased sensitivity to
striatonigral degeneration and olivopontocerebellar atrophy induced by
the mitochondrial inhibitor 3-nitropropionic acid [149]. Expression of
human α-syn using a murine myelin basic protein (MBP) promoter
results in the speciﬁc expression of α-syn in oligodendrocytes with
progressive accumulation of ﬁlamentous inclusions associated withdisruption of myelin lamina and demyelination [150]. In thesemice, the
accumulation of α-syn in oligodendrocytes results in decreased
dendritic density and loss of DA projections in the basal ganglia. In
one of theMBP/α-syn tgmouse lines expressing the highest levels ofα-
syn, severe neurological features, including ataxia and seizure activity,
resulting in premature death, is observed.
Transgenic mice expressing WT human α-syn in oligodendrocytes
also have been generated using a murine 2′, 3′-cyclic nucleotide 3′-
phosphodiesterase (CNP) promoter to drive expression [151]. The
transgene is speciﬁcally expressed in oligodendrocytes resulting in
age-dependent cytoplasmic brain and spinal cord accumulations and
the formation of ﬁbrillar inclusions. These inclusions are associated
with demyelination, demise of oligodendrocytes, age-dependent
motor impairment and brain atrophy. Injury to oligodendrocytes
results in secondary neuronal degeneration including accumulation of
perikaryal hyperphosphorylated neuroﬁlaments, degeneration of
axonal terminal, neuronal loss, and formation of neuronal inclusions
comprised of endogenous mouse α-syn.
Recently, the ﬁrst tetracyline-regulated conditional tg mice (tet-
off) expressing human wt α-syn was described [152]. To drive
inducible expression in speciﬁc neuronal populations these mice
have been cross-bred to tg mice expressing tetracycline-controlled
transactivator under the control of the hamster PrP or calcium/
calmodulin-dependent protein kinase IIα (CaMKIIα) promoter. In one
of these inducible PrP/α-syn tg mouse lines,α-syn is expressed in the
olfactory bulb, cortex, basal ganglia and cerebellum, while in another
inducible PrP/α-syn tg line expression is predominantly conﬁned to
olfactory bulb. In one of the inducible CaMKIIα/α-syn tg mouse lines,
α-syn is expressed in the olfactory bulb, cortex, basal ganglia,
hippocampus, thalamus and substantia nigra, including DA neurons.
These CaMKIIα/α-syn tg mice exhibit reductions in SN DA neurons
and hippocampal neurogenesis, without the presence of α-syn
aggregates. They demonstrate a progressive motor decline as assayed
by rotarod that cannot be reversed by turning off tg α-syn expression.
11. Studies of α-syn over-expression in adult DA neurons using
viral delivery
Several studies haveused viral vectors to expressα-syn in adult rats
or monkeys nigral DA neurons. One advantage of this approach is that
it mitigates the possible effects of early developmental expression of
α-synwith the possibility of compensatorymechanisms. Expression of
human WT, Ala30Pro or Ala53Thr α-syn in rat or monkey nigral DA
neurons using adeno-associated viral vectors that stably express the
transgene (N6 months) results in substantial and speciﬁc demise of
these DA neurons (30–80% loss), concurrent with the formation of
cellular α-syn inclusions and dystrophic neurites [153–155]. Similar
results are observed when using a lentiviral-based vector system to
express α-syn proteins in rat nigral DA neurons; however, over-
expression of rat α-syn is much less toxic [156].
12. General remarks
Although genetic and pathological studies have clearly demon-
strated the importance of α-syn in the etiology of PD, several different
mechanisms of toxicity have been proposed. These can be grouped
into 3 categories based on the monomeric/polymeric nature of the
proposed toxic species.
First, simple increases in intracellular abundance of monomeric α-
syn have been proposed as a mode of neuronal toxicity. Some studies in
cultured cellsmany support this notion; however, theseﬁndings are not
unanimous and the loss of DA neurons in the SN or other types of
neurons has not been observed in tgmice that simply over-express high
levels of α-syn. In PD or DLB patients with duplication or triplication of
the α-syn gene, where α-syn expression is increased by 50% or 100%,
respectively,α-synpathological inclusions always coincidewith disease
621E.A. Waxman, B.I. Giasson / Biochimica et Biophysica Acta 1792 (2009) 616–624(see [157] and references therein). In addition, some studies have
suggested thatα-syn expressionmaybe increased in speciﬁc brain areas
or types of neurons in individuals with sporadic PD, but these ﬁndings
have been challenged in other reports (see [158] and references
therein).
Secondly, based on in vitro data discussed above, some forms of α-
syn oligomers and protoﬁbrils have been proposed as potent toxic
speciﬁes. However, this hypothesis still lacks solid direct in vivo
studies documenting toxicity linked to the present ofα-syn oligomers,
although some models using cultured cell supports this notion.
Conversely, biochemical studies have shown that the presence of
some forms of α-syn oligomers in the midbrain of PrP/Ala53Thr α-
syn tg mice without any evidence of toxicity to DA neurons [115].
Lastly, the notion that the aberrant polymerization of α-syn into
ﬁlaments, which eventually form large intracytoplasmic inclusions,
can cause the dysfunction and the demise of neurons or oligoden-
drocytes has been support by various experimental models, as
described above. Furthermore, the involvement of α-syn aggregates
in the dysfunction and demise of neurons is suggested by the
correlations between severity of dementia and LB density in patients
with DLB [159–162]. In addition, it is likely that a profusion of smaller
α-syn aggregates in the form of neuritic and pre-synaptic α-syn
inclusions have a predominant role in impairing normal neuronal
function [74,132,163–165]. α-Syn aggregates may impair proteasome
function [166], and they may act as “sinks,” incidentally recruiting
other necessary, cellular proteins from their normal cellular functions.
α-Syn inclusions can impair cellular functions by obstructing normal
cellular trafﬁcking (including disruption of ER and Golgi apparatus),
by disrupting cell morphology, by impairing axonal transport, and by
trapping cellular components (e.g. mitochondria).
It is important to emphasize that the different alternative
mechanisms of α-syn toxicity based on the different forms of α-syn
polymers are not necessarily mutually exclusive. The presence of any
form of α-syn polymer, from small oligomers to amyloid ﬁbrils, is
abnormal and may be problematic for the normal activities of cells,
thereby resulting in neurodegeneration.
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